BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

BTG plc (BGC.L): Completion Of The Acquisition Of Protherics PLC


12/4/2008 12:15:37 PM

London, UK, 4 December 2008: BTG plc (LSE: BGC), the specialty pharmaceuticals company, is pleased to announce that all the conditions to its recommended offer for Protherics PLC (the "Acquisition") have been satisfied and the Acquisition has therefore been completed.

Accordingly, 104,044,710 new BTG ordinary shares of 10 pence each issued in connection with the Acquisition were admitted to the Official List and to trading on the London Stock Exchange at 8.00 a.m. today.

Further to the announcement made on 18 September 2008, BTG confirms that, with effect from today, Rolf Soderstrom, Finance Director of Protherics PLC, has joined the board of BTG as Chief Financial Officer and Christine Soden, the current Chief Financial Officer of BTG, has moved to the role of Chief Operating Officer.

“We are delighted to have completed this merger with Protherics, which gives us the platform to build a leading specialty pharmaceuticals business,” commented Louise Makin, BTG’s Chief Executive Officer. “Initial integration activities will focus on prioritising programmes in the development pipeline and rationalising operations to achieve the planned synergies and cost savings. We will provide an update on progress in due course.”

Following admission of the new BTG ordinary shares, the issued share capital and total voting rights in BTG are as follows:

BTG's issued share capital consists of 255,319,921 Ordinary shares of 10 pence each with voting rights attached (one vote per Ordinary share). There are no shares held in Treasury. Therefore the total number of voting rights in BTG as at 4 December 2008 is 255,319,921.

The above total voting rights figure may be used by shareholders as the denominator for the calculation by which they will determine whether they are required to notify their interests in, or a change to their interest in, BTG under the Financial Service Authority's Disclosure and Transparency Rules.

About BTG

BTG is an international specialty pharmaceuticals company that is developing and commercialising products targeting critical care, cancer, neurological and other disorders. The company is also seeking to acquire new products to develop and market to hospital specialists, and is building a sustainable business financed by revenues from sales of its critical care products and from royalties and milestone payments on partnered products. For further information, visit: www.btgplc.com.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->